NeuBase Other Current Liab from 2010 to 2024
| NBSE Stock | USD 0.41 0.01 2.38% |
Other Current Liabilities | First Reported 2004-03-31 | Previous Quarter 4.2 M | Current Value 3.4 M | Quarterly Volatility 254.9 M |
Check NeuBase Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among NeuBase main balance sheet or income statement drivers, such as Depreciation And Amortization of 1 M, Interest Expense of 20.6 K or Selling General Administrative of 14.3 M, as well as many exotic indicators such as Price To Sales Ratio of 0.48, Dividend Yield of 0.0 or PTB Ratio of 3.68. NeuBase financial statements analysis is a perfect complement when working with NeuBase Therapeutics Valuation or Volatility modules.
NeuBase | Other Current Liab |
Latest NeuBase Therapeutics' Other Current Liab Growth Pattern
Below is the plot of the Other Current Liab of NeuBase Therapeutics over the last few years. It is NeuBase Therapeutics' Other Current Liabilities historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in NeuBase Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Other Current Liab | 10 Years Trend |
|
Other Current Liab |
| Timeline |
NeuBase Other Current Liab Regression Statistics
| Arithmetic Mean | 2,057,361 | |
| Coefficient Of Variation | 82.52 | |
| Mean Deviation | 1,340,443 | |
| Median | 1,662,660 | |
| Standard Deviation | 1,697,832 | |
| Sample Variance | 2.9T | |
| Range | 5.3M | |
| R-Value | (0.06) | |
| Mean Square Error | 3.1T | |
| R-Squared | 0 | |
| Significance | 0.83 | |
| Slope | (22,515) | |
| Total Sum of Squares | 40.4T |
NeuBase Other Current Liab History
About NeuBase Therapeutics Financial Statements
There are typically three primary documents that fall into the category of financial statements. These documents include NeuBase Therapeutics income statement, its balance sheet, and the statement of cash flows. NeuBase Therapeutics investors use historical funamental indicators, such as NeuBase Therapeutics's Other Current Liab, to determine how well the company is positioned to perform in the future. Although NeuBase Therapeutics investors may use each financial statement separately, they are all related. The changes in NeuBase Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on NeuBase Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on NeuBase Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in NeuBase Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Other Current Liabilities | 1.9 M | 2 M |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectCheck out the analysis of NeuBase Therapeutics Correlation against competitors. For information on how to trade NeuBase Stock refer to our How to Trade NeuBase Stock guide.You can also try the Risk-Return Analysis module to view associations between returns expected from investment and the risk you assume.
Complementary Tools for NeuBase Stock analysis
When running NeuBase Therapeutics' price analysis, check to measure NeuBase Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NeuBase Therapeutics is operating at the current time. Most of NeuBase Therapeutics' value examination focuses on studying past and present price action to predict the probability of NeuBase Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NeuBase Therapeutics' price. Additionally, you may evaluate how the addition of NeuBase Therapeutics to your portfolios can decrease your overall portfolio volatility.
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Fundamental Analysis View fundamental data based on most recent published financial statements | |
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Top Crypto Exchanges Search and analyze digital assets across top global cryptocurrency exchanges | |
| Investing Opportunities Build portfolios using our predefined set of ideas and optimize them against your investing preferences | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance |
Is NeuBase Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of NeuBase Therapeutics. If investors know NeuBase will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about NeuBase Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (18.60) | Return On Assets (0.43) | Return On Equity (0.93) |
The market value of NeuBase Therapeutics is measured differently than its book value, which is the value of NeuBase that is recorded on the company's balance sheet. Investors also form their own opinion of NeuBase Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is NeuBase Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because NeuBase Therapeutics' market value can be influenced by many factors that don't directly affect NeuBase Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between NeuBase Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if NeuBase Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, NeuBase Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.